Pharmacokinetic properties of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 2, 2010, Pages 162-171

  Yancey, M F ^a   Merritt, D A ^a   Lesman, S P ^a   Boucher, J F ^a   Michels, G M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PALLADIA; PROTEIN TYROSINE KINASE INHIBITOR; SU 11654; TOCERANIB PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; MASTOCYTOMA; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; HALF-LIFE; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MASTOCYTOSIS, CUTANEOUS; MOLECULAR STRUCTURE; PROTEIN-TYROSINE KINASES; PYRROLES;

CANIS FAMILIARIS;

EID: 77949411632     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2009.01133.x     Document Type: Article

References (9)

1. FDA Guidance for Industry. Bioanalytical Method Validation. http://www.fda.gov/cder/guidance/4252fnl.pdf(2001).Accessed21Jan2009.
2. Flockhart, D.A. (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. http://medicine.iupui.edu/flockhart/table.htm. Accessed 21Jan2009.
3. Liao, A.T., Chien, M.B., Shenoy, N., Mendel, D.B., McMahon, G., Cherrington, J.M. & London, C. (2002) Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood, 100, 585-593.
4. London, C.A., Hannah, A.L., Zadovoskaya, R., Chien, M.B., Kollias-Baker, C., Rosenberg, M., Downing, S., Post, G., Boucher, J., Shenoy, M., Mendel, D.B., McMahon, G. & Cherrington, J.M. (2003) Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research, 9, 2755-2768.
5. London, C.A., Malpas, P.B., Wood-Follis, S.L., Boucher, J.F., Rusk, A.W., Rosenberg, M.P., Henry, C.J., Mitchener, K.L., Klein, M.K., Hintermeister, J.G., Bergman, P.J., Couto, G.C., Mauldin, G.N. & Michels, G.M. (2009) Multicenter, placebo-controlled, double-blind randomized study of oral Toceranib Phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either Local or Distant) mast cell tumor following surgical excision. Clinical Cancer Research, 15, 3856-3865.
6. Martinez, M., Augsburger, L., Johnston, T. & Jones, W.W. (2002) Applying the biopharmaceutics classification system to veterinary pharmaceutical products Part I: biopharmaceutics and formulation considerations. Adv Drug Deliver Rev, 54, 805-824.
7. Polli, J.E., Bigora, S., Piscitelli, D.A., Straughn, A.B. & Young, D. (1996) Short Communication: 'Pavlovian' food effect on the enterohepatic recirculation of piroxicam. Biopharmaceutics and Drug Disposition, 17, 635-641.
8. Pryer, N.K., Lee, L.B., Zadovaskaya, R., Xiaoming, Y., Sukbuntherng, J., Cherrington, J.M. & London, C.A. (2003) Proof of Target for SU11654: inhibition of KIT phosphorylation in Canine mast cell tumors. Clinical Cancer Research, 9, 5729-5734.
9. Yancey, M.F., Merritt, D.A., White, J.A., Marsh, S.A. & Locuson, C.W. (2009) Distribution, metabolism, and excretion of Toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics. (in press).